Evidence map›Paper›PMID 33085090›Full record

ArticleCancer2021

Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.

Sanghee Hong, Ruta Brazauskas, Kyle M Hebert, Siddhartha Ganguly, Hisham Abdel-Azim, Miguel Angel Diaz, Sara Beattie, Stefan O Ciurea, David Szwajcer, Sherif M Badawy and 30 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. The global epidemiology of acute myeloid leukaemia.Nature reviews. Clinical oncology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology. American Society of Hematology. Education Program · 2021
    Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors at 20 institutions in 10 countries.

Sanghee HongBlood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.
Ruta BrazauskasCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Kyle M HebertCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Hisham Abdel-AzimDivision of Hematology, Oncology, and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Miguel Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Sara BeattieDepartment of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Stefan O CiureaThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8597-3271
David SzwajcerUniversity of Manitoba, Winnipeg, Manitoba, Canada.
Sherif M BadawyDivision of Hematology, Oncology, and Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Alois A GratwohlUniversity Hospital Basel, Basel, Switzerland.
Charles LeMaistreHematology and Bone Marrow Transplant, Sarah Cannon, Nashville, Tennessee.
Mahmoud D S M AljurfDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Neel S BhattFred Hutchinson Cancer Research Center, Seattle, Washington.
Nosha FarhadfarDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.ORCID 0000-0002-2752-9604
Jean A YaredBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Ayami YoshimiDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Freiburg, Germany.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Usama GergisThomas Jefferson University, Philadelphia, Pennsylvania.
Amer M BeitinjanehUniversity of Miami, Miami, Florida.
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
Hillard LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
Jason LawDivision of Pediatric Hematology/Oncology, Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts.
Matthew UlricksonBanner MD Anderson Cancer Center, Gilbert, Arizona.
Hasan HashemDivision of Pediatric Hematology/Oncology and Bone Marrow Transplantation, King Hussein Cancer Center, Amman, Jordan.
Hélène SchoemansDepartment of Hematology, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.
David RizzieriDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-3304-9965
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Bronwen E ShawCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.ORCID 0000-0003-3317-1896
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0002-0577-3155
William A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Shahrukh HashmiDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8914-7927
Theresa HahnDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Stephanie J LeeCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
J Douglas RizzoCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Navneet S MajhailBlood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0001-7082-891X
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Medical College of Wisconsin · USCleveland Clinic · USBanner MD Anderson Cancer CenterBaylor College of Medicine · USDokkyo Medical University · JPDuke University · USFred Hutch Cancer Center · USHospital Infantil Universitario Niño Jesús · ESKing Faisal Specialist Hospital & Research Centre · SAKing Hussein Cancer Center · JOKU Leuven · BEMayo Clinic · USNorthwestern University · USRoswell Park Comprehensive Cancer Center · USSarah Cannon · USSt. Jude Children's Research Hospital · USThe University of Texas MD Anderson Cancer Center · USThomas Jefferson University · USTufts Medical Center · USUniversity Hospital of Basel · CH

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2M
Hematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9M
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5M
Immuno and Epigenetics of Hematopoietic Cell TransplantationR01CA218285 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2017 to 2026
$5.6M
The role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4M
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5M
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6M
Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M
Improving Survivorship Care for Adolescents and Young Adults: a Mixed Methods Study of Alignment with the National Standards for Survivorship CareU01CA246659 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S · 2020 to 2025
$3.6M
AbbVieActinium PharmaceuticalsAdaptive BiotechnologiesAdienne SAAlloVirAmgenAnthemAstellas Pharma USAstraZenecaAtara BiotherapeuticsBluebird BioBristol-Myers SquibbCelgeneChimerixCSL BehringCytoSen TherapeuticsDaiichi Sankyo CoGamida-CellGenzymeGlaxoSmithKlineHealth Resources and Services Administration (HRSA) HHSH250201700006CHealth Resources and Services Administration (HRSA) HHSH250201700007CHealth Resources and Services Administration (HRSA) SC1MC31881-01-00HistoGeneticsIncyte CorporationJanssen BiotechJanssen/Johnson & JohnsonJanssen PharmaceuticalsJazz PharmaceuticalsKiadis PharmaKite PharmaKyowa KirinLegend BiotechMagenta TherapeuticsMallinckrodt LLCMedac GmbHMedical College of WisconsinMerck & Company, IncMerck Sharp & Dohme CorpMesoblastMillennium (the Takeda Oncology Co)Miltenyi BiotecNCI NIH HHS P01 CA111412NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA215134NCI NIH HHS R01 CA218285NCI NIH HHS R01 CA231141NCI NIH HHS U01 CA246659NCI NIH HHS U24 CA076518NHLBI NIH HHS K23 HL150232NHLBI NIH HHS R01 HL126589NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL130388NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS R01 AI128775NIAID NIH HHS U01 AI069197NIAID NIH HHS U01 AI126612NIH HHS P30 CA016672Novartis OncologyNovartis Pharmaceuticals CorporationOffice of Naval Research N00014-18-1-2850Office of Naval Research N00014-18-1-2888Office of Naval Research N00014-20-1-2705Omeros CorporationOncoImmune, IncOrca Biosystems, IncPfizerPharmacyclics, LLCRegeneron PharmaceuticalsREGiMMUNE CorpSanofi GenzymeSeattle GeneticsSobi, IncTakeda OncologyTakeda PharmaTerumo BCTThe National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) U24CA076518Viracor EurofinsXenikos BV
6 · The paper itself

Abstract

backgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.

methodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.

resultsThe median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.

conclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.

Indexed as

Community Health PlanningAdolescentAdultAgedAged, 80 and overFemaleHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedNeoplasm Recurrence, LocalPublic HealthRisk FactorsTransplantation, HomologousTreatment Outcomeallogeneic transplantcommunity healthhematopoietic cell transplantationsurvival

Identifiers

PMID33085090
PMCPMC7855526
OpenAlexW3094406723

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.